Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Trexquant Investment LP

Trexquant Investment LP grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 101.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 966,049 shares of the biopharmaceutical company's stock after acquiring an additional 486,827 shares during the period. Trexquant Investment LP owned about 0.32% of Amicus Therapeutics worth $9,100,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Headlands Technologies LLC increased its holdings in Amicus Therapeutics by 599.0% during the 4th quarter. Headlands Technologies LLC now owns 34,812 shares of the biopharmaceutical company's stock worth $328,000 after purchasing an additional 29,832 shares during the period. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after buying an additional 4,497,950 shares during the period. denkapparat Operations GmbH purchased a new stake in shares of Amicus Therapeutics during the fourth quarter worth approximately $171,000. Norges Bank acquired a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $29,033,000. Finally, Prudential Financial Inc. lifted its stake in Amicus Therapeutics by 4.6% in the fourth quarter. Prudential Financial Inc. now owns 479,449 shares of the biopharmaceutical company's stock worth $4,516,000 after acquiring an additional 21,000 shares during the last quarter.

Remove Ads

Amicus Therapeutics Stock Performance

Shares of FOLD stock traded down $0.50 during mid-day trading on Friday, hitting $7.50. The stock had a trading volume of 3,184,754 shares, compared to its average volume of 2,536,159. Amicus Therapeutics, Inc. has a fifty-two week low of $7.39 and a fifty-two week high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The company's 50-day simple moving average is $9.12 and its 200-day simple moving average is $9.86. The firm has a market cap of $2.30 billion, a PE ratio of -41.67, a PEG ratio of 1.51 and a beta of 0.69.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on FOLD shares. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.